The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 30 Jan 2018
At a glance
- Drugs Maraviroc (Primary) ; Boceprevir
- Indications Hepatitis C; HIV-1 infections
- Focus Pharmacokinetics
- 24 Jan 2018 Status changed from recruiting to completed.
- 31 May 2013 Planned end date changed from 1 Sep 2012 to 1 Feb 2014 as reported by ClinicalTrials.gov record.
- 03 Jul 2012 New trial record